NPRA1985

NPRA1985 | Joined since 2020-09-03

Investing Experience -
Risk Profile -

Followers

0

Following

0

Blog Posts

0

Threads

3,415

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
3,415
Past 30 days
0
Past 7 days
0
Today
0

User Comments
Stock

2020-11-24 09:57 | Report Abuse

@limit_up_soon I was watching your post and then my neighbor came and we watched it together. He said this post really changed his life and it touched my heart. My village people are so grateful. Am proud to say cool post wow thanks for sharing

Stock

2020-11-24 09:36 | Report Abuse

@purple_rain Great article. Thanks for sharing !

Stock

2020-11-24 09:33 | Report Abuse

Must be Topglove dragging down the healthcare index

Stock

2020-11-24 09:32 | Report Abuse

Most vaccine counters and glove counters red....

Stock
Stock
Stock
Stock
Stock
Stock

2020-11-24 03:10 | Report Abuse

BN utama kepentingan gabungan, suara akar umbi

Ditanya sama ada BN akan kekal memberi sokongan kepada Belanjawan 2021 secara bersyarat seperti yang diumumkan sebelum ini, Hishamuddin berkata, itu adalah keputusan parti setakat ini.

https://www.bharian.com.my/berita/nasional/2020/11/757537/bn-utama-kepentingan-gabungan-suara-akar-umbi

Stock

2020-11-24 03:10 | Report Abuse

BN utama kepentingan gabungan, suara akar umbi

Ditanya sama ada BN akan kekal memberi sokongan kepada Belanjawan 2021 secara bersyarat seperti yang diumumkan sebelum ini, Hishamuddin berkata, itu adalah keputusan parti setakat ini.

https://www.bharian.com.my/berita/nasional/2020/11/757537/bn-utama-kepentingan-gabungan-suara-akar-umbi

Stock

2020-11-24 03:09 | Report Abuse

BN utama kepentingan gabungan, suara akar umbi

Ditanya sama ada BN akan kekal memberi sokongan kepada Belanjawan 2021 secara bersyarat seperti yang diumumkan sebelum ini, Hishamuddin berkata, itu adalah keputusan parti setakat ini.

https://www.bharian.com.my/berita/nasional/2020/11/757537/bn-utama-kepentingan-gabungan-suara-akar-umbi

Stock

2020-11-24 03:09 | Report Abuse

BN utama kepentingan gabungan, suara akar umbi

Ditanya sama ada BN akan kekal memberi sokongan kepada Belanjawan 2021 secara bersyarat seperti yang diumumkan sebelum ini, Hishamuddin berkata, itu adalah keputusan parti setakat ini.

https://www.bharian.com.my/berita/nasional/2020/11/757537/bn-utama-kepentingan-gabungan-suara-akar-umbi

Stock

2020-11-24 03:03 | Report Abuse

BN utama kepentingan gabungan, suara akar umbi

Ditanya sama ada BN akan kekal memberi sokongan kepada Belanjawan 2021 secara bersyarat seperti yang diumumkan sebelum ini, Hishamuddin berkata, itu adalah keputusan parti setakat ini.

https://www.bharian.com.my/berita/nasional/2020/11/757537/bn-utama-kepentingan-gabungan-suara-akar-umbi

Stock

2020-11-24 03:02 | Report Abuse

BN utama kepentingan gabungan, suara akar umbi

Ditanya sama ada BN akan kekal memberi sokongan kepada Belanjawan 2021 secara bersyarat seperti yang diumumkan sebelum ini, Hishamuddin berkata, itu adalah keputusan parti setakat ini.

https://www.bharian.com.my/berita/nasional/2020/11/757537/bn-utama-kepentingan-gabungan-suara-akar-umbi

Stock

2020-11-24 01:57 | Report Abuse

AstraZeneca shares fall after efficacy findings for Covid-19 vaccine

Analysts say ‘lower efficacy for higher dose’ needs explaining, as results below those of rivals

AstraZeneca shares fell after the drugmaker announced efficacy results for its Covid-19 vaccine that were below those reported by rivals Pfizer/BioNTech and Moderna.

Results from the phase 3 trial showed the vaccine developed with the University of Oxford can protect 70.4% of people from becoming ill and, in a surprise result, up to 90% if a lower first dose is used.

This is lower than the 95% efficacy reported for vaccines developed by the US drugmaker Pfizer and the German biotech BioNTech, and the US biotech Moderna. Analysts said the AstraZeneca/Oxford results left some unanswered questions.

Maxim Jacobs, of the investment research firm Edison Group, said: “It’s not normal for there to be lower efficacy for a higher dose, it can happen but it’s rare. There are some potential explanations, such as the vector immune response, but it’s hard to know without more data.”

James Bevan, the chief investment officer at the fund manager CCLA, told Sky News the efficacy data had been “rather less than had been anticipated by the market”.

https://www.theguardian.com/business/2020/nov/23/astrazeneca-shares-fall-after-efficacy-findings-for-covid-19-vaccine-results

Stock

2020-11-24 00:56 | Report Abuse

@Sweetchocalates Wrong. One is base on mrNA , the other is based on DNA. The adenovirus is merely a vehicle to deliver the DNA to the host cells.

Stock

2020-11-24 00:38 | Report Abuse

@BuahCiku Who is Scenery and how do you know him in the first place? You guys long lost friends?

Stock

2020-11-24 00:00 | Report Abuse

@BuahCiku Lol do you know the meaning of number of outstanding shares and float? Go do some research and compare Titijaya versus Kanger, then you know why.

Stock

2020-11-23 23:56 | Report Abuse

@SleepingForest Exactly, no need to overanalyse and think so hard....Its either you enter or you dont thats it. Nothing to discuss lol

Stock

2020-11-23 23:44 | Report Abuse

@Scenery I totally agree with you. Friendship is the biggest conman here Pity all his blind followers here believing in his vaccine fantasies.

Stock

2020-11-23 23:42 | Report Abuse

@Friendship Talking about fool people. You are the biggest culprit here lol Keep on misleading people on an on with your made up fantasy that Titijaya will be signing the vaccine agreement with Sinopharm soon kekeke Keep on dreaming until 2050 lol

Stock

2020-11-23 23:41 | Report Abuse

@Friendship Yea go on living in your titijaya dream bubble lol Sweet dream kekeke

Stock

2020-11-23 23:40 | Report Abuse

@MadCow75 All these keyboard warriors suddenly appearing out of nowhere here acting sooo soooo "concerned" lolol like we don't know their ulterior motives or hidden agenda lol

Stock

2020-11-23 23:37 | Report Abuse

@jasomred79 Who the hell cares whether tiny or small or medium or big or large. As long as they are part of the Sinopharm Group, thats all that matters to me. If you dont believe in Kanger, why waste your energy here type so much lolol . Obviously you have an ulterior motive or hidden agenda here otherwise you wouldnt be here acting so "concerned" LOL !!

Stock

2020-11-23 22:40 | Report Abuse

@Friendship I was watching your post and then my neighbor came and we watched it together. He said this post really changed his life and it touched my heart. My village people are so grateful. Am proud to say cool post wow thanks for sharing

Stock

2020-11-23 22:12 | Report Abuse

UMNO linked company no need to worry mah. Now UMNO is kingmaker anything can happen.

Stock

2020-11-23 22:11 | Report Abuse

@Sweetchocalates Wrong, Cansino does not use the same tech as moderna or pfizer. It uses the same tech as Johson & Johnson and Astrazeneca/Oxford (Today reported average 70% efficacy). The vaccine tech is adenovirus vector vaccine.

Stock

2020-11-23 21:58 | Report Abuse

@jasonred79 No wonder you gone cuckoo. Cos you are in Topglove kekeke. Understandable. I would also go cuckoo if i read this bad news. The price of Topglove will be greatly affected by this news.

28 Top Glove factories in Klang to close after 1,067 Covid-19 cases detected
https://www.freemalaysiatoday.com/category/nation/2020/11/23/28-top-glove-factories-in-klang-to-close-in-stages/

Stock

2020-11-23 21:54 | Report Abuse

@rockriz Some people not much on brains. Maybe due to mco too long, gone cuckoo. Case in point @jasonred79

Stock

2020-11-23 21:49 | Report Abuse

@jasonred79 I was re-watching your post and then my neighbor came and we re-watched it together. He said this post really changed his life and it touched my heart. My village people are so grateful. Am proud to say cool post wow thanks for sharing

Stock

2020-11-23 21:47 | Report Abuse

@jasonred79 Cos you re in Metronic lol

Stock

2020-11-23 21:27 | Report Abuse

The vaccine, developed with the University of Oxford, showed an average efficacy of 70% in preventing the coronavirus, according to the company. However, that is an average of two dosing regimens — one involving two full doses at least a month apart that proved to be 62% effective. A second regimen, involving a half dose followed by a full does at least one month later was 90% effective, the company said.

https://www.wgbh.org/news/science-and-technology/2020/11/23/u-k-coronavirus-trial-promises-highly-effective-new-vaccine

Stock

2020-11-23 21:27 | Report Abuse

The vaccine, developed with the University of Oxford, showed an average efficacy of 70% in preventing the coronavirus, according to the company. However, that is an average of two dosing regimens — one involving two full doses at least a month apart that proved to be 62% effective. A second regimen, involving a half dose followed by a full does at least one month later was 90% effective, the company said.

https://www.wgbh.org/news/science-and-technology/2020/11/23/u-k-coronavirus-trial-promises-highly-effective-new-vaccine

Stock

2020-11-23 21:26 | Report Abuse

The vaccine, developed with the University of Oxford, showed an average efficacy of 70% in preventing the coronavirus, according to the company. However, that is an average of two dosing regimens — one involving two full doses at least a month apart that proved to be 62% effective. A second regimen, involving a half dose followed by a full does at least one month later was 90% effective, the company said.

https://www.wgbh.org/news/science-and-technology/2020/11/23/u-k-coronavirus-trial-promises-highly-effective-new-vaccine

Stock

2020-11-23 21:26 | Report Abuse

The vaccine, developed with the University of Oxford, showed an average efficacy of 70% in preventing the coronavirus, according to the company. However, that is an average of two dosing regimens — one involving two full doses at least a month apart that proved to be 62% effective. A second regimen, involving a half dose followed by a full does at least one month later was 90% effective, the company said.

https://www.wgbh.org/news/science-and-technology/2020/11/23/u-k-coronavirus-trial-promises-highly-effective-new-vaccine

Stock

2020-11-23 21:26 | Report Abuse

The vaccine, developed with the University of Oxford, showed an average efficacy of 70% in preventing the coronavirus, according to the company. However, that is an average of two dosing regimens — one involving two full doses at least a month apart that proved to be 62% effective. A second regimen, involving a half dose followed by a full does at least one month later was 90% effective, the company said.

https://www.wgbh.org/news/science-and-technology/2020/11/23/u-k-coronavirus-trial-promises-highly-effective-new-vaccine

Stock

2020-11-23 21:17 | Report Abuse

@jasonred79 FYI Medigen Vaccine Biologics Corporation (MVC) linked to Metronic is only in phase 1 clinical trials lol By the time it reaches phase 3, there will be not enough cases of the Covid-19 emerging in the study population in order to conduct the statistical analysis as most people would already have been vaccinated with other approved vaccines by then.

Stock

2020-11-23 20:55 | Report Abuse

@jasonred79 I was watching your post and then my neighbor came and we watched it together. He said this post really changed his life and it touched my heart. My village people are so grateful. Am proud to say cool post wow thanks for sharing

Stock

2020-11-23 17:20 | Report Abuse

@my2020 I have no doubt that both of Sinopharm vaccines are leading the vaccine race globally. I have been doing lots of research and came to that conclusion.

Stock
Stock

2020-11-23 17:17 | Report Abuse

@limitup1188 Okay good luck with your fake news Titijaya. Enjoy and have fun!